In addition to PD-1 and CTLA-4, BTLA is also an immune checkpoint, and is ligated by HVEM to inhibit T cell activation and survival [13,14,15,16], hence BTLA blockade can enhance cancer immunotherapy [17,18]. Here, CTLA4 is linked to cancer.